Abstract:Cancer Biotherapy & RadiopharmaceuticalsVol. 32, No. 4 CorrectionCorrection to: Cancer Biother Radiopharm 2017;32(3):101–110Published Online:1 May 2017https://doi.org/10.1089/cbr.2016.2156.correxAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Correction to: Cancer Biother Radiopharm 2017;32(3):101–110." Cancer Biotherapy and Radiopharmaceuticals, 32(4), p. 147FiguresReferencesRelatedDetails Volume 32Issue 4May 2017 InformationCopyright 2017, Mary Ann Liebert, Inc.To cite this article:Correction to: Cancer Biother Radiopharm 2017;32(3):101–110.Cancer Biotherapy and Radiopharmaceuticals.May 2017.147-147.http://doi.org/10.1089/cbr.2016.2156.correxOnline Ahead of Print:May 5, 2017Published in Volume: 32 Issue 4: May 1, 2017PDF download

Correction: De Sanctis et al. Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event. Cancers 2024, 16, 2630

Correction: Russo et al. The Role of Dielectrophoresis for Cancer Diagnosis and Prognosis. Cancers 2022, 14, 198

Correction: Srinivasan Rajsri et al. Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection. Cancers 2023, 15, 2866

Correction: Harper et al. Alberta Childhood Cancer Survivorship Research Program. Cancers 2023, 15, 3932

Correction: Antón-García et al. TGFβ1-Induced EMT in the MCF10A Mammary Epithelial Cell Line Model Is Executed Independently of SNAIL1 and ZEB1 but Relies on JUNB-Coordinated Transcriptional Regulation. Cancers 2023, 15, 588

Correction: Marin et al. Clinical Correlations between Serological Markers and Endometrial Cancer. Cancers 2024, 16, 1935

Corrigendum to ‘Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics’ [Genes & Diseases10 (2023) 1367–1401]

Correction: Ádány et al. Discrepancies Between the Spatial Distribution of Cancer Incidence and Mortality as an Indicator of Unmet Needs in Cancer Prevention and/or Treatment in Hungary. Cancers 2024, 16, 2917

Correction To: Cancer Biother Radiopharm 2017;32(3):101–110

Erratum: Investigating tumor immunogenicity in breast cancer: deciphering the tumor immune response to enhance therapeutic approaches

Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Correction: Zhang et al. Clinical Management of Low Anterior Resection Syndrome: Review of the Current Diagnosis and Treatment. Cancers 2023, 15, 5011

Correction: Becker et al. Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response. Cancers 2023, 15, 5597

Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283

Correction: Lepore Signorile et al. c-MYC Protein Stability Is Sustained by MAPKs in Colorectal Cancer. Cancers 2022, 14, 4840

Correction: Mukherjee et al. Homo and Heterotypic Cellular Cross-Talk in Epithelial Ovarian Cancer Impart Pro-Tumorigenic Properties through Differential Activation of the Notch3 Pathway. Cancers 2022, 14, 3365

Correction: Gupta et al. Androgen Receptor Activation Induces Senescence in Thyroid Cancer Cells. Cancers 2023, 15, 2198

Correction to 'The levels of p53 govern the hierarchy of DNA damage tolerance pathway usage'

Correction: Huang et al. Endogenous Propionibacterium acnes Promotes Ovarian Cancer Progression via Regulating Hedgehog Signalling Pathway. Cancers 2022, 14, 5178

Correction: Gravina et al. ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma. Cancers 2022, 14, 289

Correction: Ishikawa et al. Systematic Review of Beta-Lactam vs. Beta-Lactam plus Aminoglycoside Combination Therapy in Neutropenic Cancer Patients. Cancers 2024, 16, 1934